Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.

Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H, COMFORT-I investigators. · 2017

Read Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. by Verstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H, COMFORT-I investigators. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5322633.txt.

Description

Srdan Verstovsek and co-authors gave the final results of a drug trial in the Journal of Hematology & Oncology in 2017. The trial, COMFORT-I, tested ruxolitinib in myelofibrosis, a bone marrow disease that swells the spleen and cuts survival. The drug blocks two signal proteins, JAK1 and JAK2. It was the first drug cleared for this disease.

Patients in Australia, Canada, and the United States were split by chance to the drug or a dummy pill, with no one told who got what. About one hundred and fifty five people started on the drug. Early results had shown spleen shrinkage and longer life. At five years, the spleen gains lasted a long span for many. No patients stayed on the dummy pill, as most had crossed to the drug.

Catalog record

CREATORVerstovsek S, Mesa RA, Gotlib J, Gupta V, DiPersio JF, Catalano JV, Deininger MW, Miller CB, Silver RT, Talpaz M, Winton EF, Harvey JH, Arcasoy MO, Hexner EO, Lyons RM, Paquette R, Raza A, Jones M, Kornacki D, Sun K, Kantarjian H, COMFORT-I investigators.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5322633

Browse the full library · About the Tower of Babel